Abstract
Advanced therapy medicinal products (ATMPs), including gene therapies, cell therapies, and tissue engineering products, are developed to target incurable diseases by interfering with the genetic or cellular mechanism. Measuring patient-reported outcomes (PROs) for ATMPs may help aid reimbursement decisions in the absence of outcome data. Therefore, this research aimed to understand the importance of PROs in evaluating ATMPs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
